Rubicon Research Limited (NSE:RUBICON)

India · Delayed Price · Currency is INR

773.60

-17.00 (-2.15%)

At close: Mar 25, 2026

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.)	12.84B	8.54B	3.94B	3.14B	3.15B
Pharmaceutical Products (Generics, Speciality, API, Related Services, Etc.) Growth	50.40%	116.99%	25.50%	-0.37%	-
Total	12.84B	8.54B	3.94B	3.14B	3.15B
Total Growth	50.40%	116.99%	25.50%	-0.37%	-

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Millions INR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
India	99.67M	109.92M	118.31M	54.94M	1.07M
India Growth	-9.33%	-7.09%	115.34%	5044.19%	-
USA	12.65B	8.32B	3.67B	2.91B	3.07B
USA Growth	52.09%	126.65%	26.01%	-5.29%	-
Others	93.82M	111.84M	147.25M	168.46M	71.30M
Others Growth	-16.11%	-24.05%	-12.59%	136.27%	-
Total	12.84B	8.54B	3.94B	3.14B	3.15B
Total Growth	50.40%	116.99%	25.50%	-0.37%	-

Source: S&P Global Market Intelligence.